Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR AmyloidosisBusiness Wire • 12/08/22
Alnylam Pharmaceuticals Offers Proven, Undervalued RNAi Platform, But Doubts Around ATTR Program RemainSeeking Alpha • 10/31/22
Alnylam: Good Start For Amvuttra, Unanswered Regulatory Questions On OnpattroSeeking Alpha • 10/31/22
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive YearBusiness Wire • 10/27/22
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 10/27/22
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period ActivityBusiness Wire • 10/27/22
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q3 Earnings Expected to DeclineZacks Investment Research • 10/20/22
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?Investors Business Daily • 10/20/22
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial ResultsBusiness Wire • 10/13/22
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1Business Wire • 10/07/22
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual MeetingBusiness Wire • 09/30/22
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 PolyneuropathyBusiness Wire • 09/20/22
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy VolunteersBusiness Wire • 09/15/22
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy VolunteersPRNewsWire • 09/15/22